Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol to Boost Immunotherapy in Advanced GI Cancers
NCT05451043Phase 2Active, not recruiting
- Sponsor
- American Health Staffing Group
- Start
- Jul 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of propranolol in pancreatic adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), sponsored by American Health Staffing Group. Started Jul 2023; status: active, not recruiting.
02
Drugs
propranolol
03
Conditions
pancreatic adenocarcinoma (PDAC)hepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05451043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05451043.